Disease Domain | Count |
---|---|
Infectious Diseases | 9 |
Neoplasms | 4 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Prophylactic vaccine | 8 |
Monoclonal antibody | 2 |
Virus-like particle vaccine | 1 |
Multivalent vaccine | 1 |
Genetically engineered subunit vaccine | 1 |
Target |
Mechanism SARS-CoV-2 S protein inhibitors |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date05 Dec 2022 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date31 Dec 2019 |
Target- |
Mechanism Immunostimulants |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date01 Dec 2011 |
Start Date11 Apr 2025 |
Sponsor / Collaborator |
Start Date31 Mar 2025 |
Sponsor / Collaborator ![]() [+1] |
Start Date06 Apr 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Human papillomavirus 16/18 vaccine recombinant bivalent(Xiamen Innovax) | Uterine Cervical Cancer More | Approved |
Hepatitis E vaccine recombinant(Xiamen Innovax Biotech Co. Ltd.) | Hepatitis E More | Approved |
DelNS1-2019-nCoV-RBD-OPT1(Beijing Wantai Biological) ( SARS-CoV-2 S protein ) | COVID-19 More | Approved |
9-Valent HPV Vaccine(Xiamen Innovax) | Penile Neoplasms More | Phase 3 |
Human papillomavirus recombinant vaccine nonavalent (Xiamen Innovax Biotech) | Uterine Cervical Cancer More | Phase 3 |